NewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial Transcript

🇺🇸 Seeking Alpha (US) —

AI Summary

NewAmsterdam Pharma Company N.V. provides an update on its clinical development and interim analysis for the PREVAIL trial. The discussion highlights the company's ongoing efforts in advancing therapies.

Markets Health NewAmsterdam Pharma clinical development PREVAIL trial healthcare biopharmaceutical

Read original source →